Beta-blockers,120 angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),250 spironolactone,251 and angiotensin receptor-neprilysin inhibitor (ARNI; valsartan–sacubitril)252 have been associated with a reduced risk of arrhythmia and SCD in patients with HF with reduced LVEF (HFrEF). This evidence concerns the gene ACE and cardiac arrhythmia.